Veru (VERU) Downgraded to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Veru (NASDAQ:VERU) from a buy rating to a hold rating in a report issued on Wednesday, Zacks.com reports.

According to Zacks, “Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL. “

Other analysts also recently issued reports about the stock. Maxim Group set a $6.00 price target on shares of Veru and gave the stock a buy rating in a research note on Thursday, February 14th. CIBC assumed coverage on shares of Veru in a research note on Wednesday, March 20th. They issued an outperform rating and a $5.00 price target for the company. Oppenheimer assumed coverage on shares of Veru in a research note on Tuesday, March 19th. They issued an outperform rating and a $5.00 price target for the company. Finally, HC Wainwright reissued a buy rating and issued a $4.50 price target on shares of Veru in a research note on Wednesday, January 23rd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $4.40.

Veru stock opened at $1.41 on Wednesday. The company has a quick ratio of 1.30, a current ratio of 1.58 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $88.46 million, a price-to-earnings ratio of -3.62 and a beta of 0.91. Veru has a twelve month low of $1.18 and a twelve month high of $2.37.

Veru (NASDAQ:VERU) last posted its quarterly earnings results on Wednesday, February 13th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.01. The business had revenue of $6.37 million during the quarter, compared to the consensus estimate of $9.71 million. Veru had a negative net margin of 111.10% and a negative return on equity of 60.83%. On average, equities analysts anticipate that Veru will post -0.19 EPS for the current fiscal year.

In other Veru news, insider Mitchell Shuster Steiner sold 49,899 shares of the business’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $1.53, for a total value of $76,345.47. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders acquired 38,681 shares of company stock worth $53,206 and sold 125,600 shares worth $184,632. 29.50% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new position in shares of Veru in the first quarter valued at about $95,000. Geode Capital Management LLC increased its position in shares of Veru by 115.4% in the fourth quarter. Geode Capital Management LLC now owns 215,601 shares of the company’s stock valued at $301,000 after acquiring an additional 115,506 shares during the period. BlackRock Inc. increased its position in shares of Veru by 9.3% in the fourth quarter. BlackRock Inc. now owns 128,766 shares of the company’s stock valued at $180,000 after acquiring an additional 10,956 shares during the period. Vanguard Group Inc increased its position in shares of Veru by 1.2% in the third quarter. Vanguard Group Inc now owns 1,199,963 shares of the company’s stock valued at $1,704,000 after acquiring an additional 13,650 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of Veru by 328.8% in the third quarter. Dimensional Fund Advisors LP now owns 102,909 shares of the company’s stock valued at $146,000 after acquiring an additional 78,909 shares during the period. Hedge funds and other institutional investors own 8.64% of the company’s stock.

About Veru

Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

Further Reading: Quiet Period

Get a free copy of the Zacks research report on Veru (VERU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.